Indaptus Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 21, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Yang Ting filed an amended Schedule 13D/A for Indaptus Therapeutics on October 21, 2026. The filing is an amendment to a prior beneficial ownership disclosure, but the specific details of the ownership stake, share count, percentage held, or what changed are not disclosed in the header/metadata provided.
Why this rating
Schedule 13D/A amendments are routine regulatory filings for ownership disclosures. Without concrete data on stake size or changes relative to Indaptus's $5.8M market cap, this appears procedural. Cannot assess materiality without amendment details.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.